{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:10:19Z","timestamp":1791868219843,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.diabres.2025.112333","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:52:06Z","timestamp":1750420326000},"page":"112333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The association of weight status with glycemic control, diabetes related complications and anti-hyperglycemic medication use in patients with type 2 diabetes mellitus: The results of the Australian National Diabetes Audit (ANDA) 2015\u20132022"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-0726","authenticated-orcid":false,"given":"N.","family":"Szwarcbard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gasevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2693-5034","authenticated-orcid":false,"given":"A.","family":"Earnest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Andrikopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Wischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sumithran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112333_b0005","unstructured":"IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2021."},{"key":"10.1016\/j.diabres.2025.112333_b0010","unstructured":"Diabetes: Word Health Organization; 2020 [updated 08\/06\/2020. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"10.1016\/j.diabres.2025.112333_b0015","unstructured":"Diabetes. Cat. no. CVD 82 Canberra: AIHW: Australian Institute of Health and Welfare; 2020 [updated 15\/07\/2020. Available from: https:\/\/www.aihw.gov.au\/reports\/diabetes\/diabetes."},{"key":"10.1016\/j.diabres.2025.112333_b0020","unstructured":"The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment. Geneva: World Health Organization; 2020."},{"key":"10.1016\/j.diabres.2025.112333_b0025","unstructured":"Type 2 diabetes: Diabetes Australia; [Available from: https:\/\/www.diabetesaustralia.com.au\/about-diabetes\/type-2-diabetes\/."},{"key":"10.1016\/j.diabres.2025.112333_b0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/DMSO.S67400","article-title":"Mechanism linking diabetes mellitus and obesity","volume":"7","author":"Al-Goblan","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"11","key":"10.1016\/j.diabres.2025.112333_b0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.115.306825","article-title":"Epidemiology of obesity and diabetes and their cardiovascular complications","volume":"118","author":"Bhupathiraju","year":"2016","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.diabres.2025.112333_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13082231","article-title":"Potential therapeutic targets in obesity, sleep apnea, diabetes, and fatty liver disease","volume":"13","author":"Gu","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2025.112333_b0045","unstructured":"National Diabetes Audit Executive Summary 2009-2010. The NHS Information Centre; 2011."},{"key":"10.1016\/j.diabres.2025.112333_b0050","unstructured":"National Diabetes Statistics Report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2020."},{"key":"10.1016\/j.diabres.2025.112333_b0055","unstructured":"Obesity and overweight: World Health Organization; 2022 [updated 01\/03\/2024. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"issue":"2","key":"10.1016\/j.diabres.2025.112333_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000496624","article-title":"Impact of obesity on the metabolic control of type 2 diabetes: results of the Turkish Nationwide Survey of Glycemic and other metabolic parameters of patients with diabetes mellitus (TEMD Obesity Study)","volume":"12","author":"Sonmez","year":"2019","journal-title":"Obes Facts"},{"issue":"2","key":"10.1016\/j.diabres.2025.112333_b0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jdiacomp.2015.11.016","article-title":"Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011","volume":"30","author":"Bae","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2025.112333_b0070","doi-asserted-by":"crossref","first-page":"153 -","DOI":"10.1186\/1471-2261-14-153","article-title":"Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage","volume":"14","author":"V\u00e1zquez","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"issue":"32","key":"10.1016\/j.diabres.2025.112333_b0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011807","article-title":"Association of obesity and risk of diabetic retinopathy in diabetes patients: a meta-analysis of prospective cohort studies","volume":"97","author":"Zhu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.diabres.2025.112333_b0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41387-017-0012-y","article-title":"Associations between body mass index and the risk of renal events in patients with type 2 diabetes","volume":"8","author":"Mohammedi","year":"2018","journal-title":"Nutr Diab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112333_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.14423\/SMJ.0000000000000214","article-title":"Relation between BMI and diabetes mellitus and its complications among US older adults","volume":"108","author":"Gray","year":"2015","journal-title":"South Med J"},{"issue":"1","key":"10.1016\/j.diabres.2025.112333_b0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/clinem\/dgz032","article-title":"Association between body mass index and stroke risk among patients with type 2 diabetes","volume":"105","author":"Shen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"28","key":"10.1016\/j.diabres.2025.112333_b0095","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/eurheartj\/ehaa293","article-title":"Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial","volume":"41","author":"Doehner","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2025.112333_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168247","article-title":"Body mass index-related mortality in patients with type 2 diabetes and heterogeneity in obesity paradox studies: a dose-response meta-analysis","volume":"12","author":"Kwon","year":"2017","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.diabres.2025.112333_b0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11886-013-0446-3","article-title":"The obesity paradox in diabetes","volume":"16","author":"Carnethon","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.diabres.2025.112333_b0110","unstructured":"Australian Diabetes Clinical Quality Registry (ADCQR): Monash University; 2024 [updated Oct 2024. Available from: https:\/\/www.monash.edu\/medicine\/sphpm\/adcqr\/home."},{"key":"10.1016\/j.diabres.2025.112333_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7547-4-1","article-title":"The association between diabetes related medical costs and glycemic control: a retrospective analysis","volume":"4","author":"Oglesby","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.diabres.2025.112333_b0120","unstructured":"The Pathology Service of St Vincent's Hospital - Estimation of the Glomerular Filtration Rate [Available from: http:\/\/www.sydpath.stvincents.com.au\/eGFR.htm."},{"key":"10.1016\/j.diabres.2025.112333_b0125","doi-asserted-by":"crossref","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-98.","DOI":"10.1007\/s00125-018-4729-5"},{"key":"10.1016\/j.diabres.2025.112333_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14506","article-title":"Trends in glycaemic control and drug use in males and females with type 2 diabetes: results of the Australian National Diabetes Audit from 2013 to 2019","author":"Xiang","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112333_b0135","unstructured":"Ozempic (semaglutide) shortage 2022 - 2025: Australian Government Department of Health and Aged Care Therapeutic Goods Administration; 2025 [updated 12\/02\/2025. Available from: https:\/\/www.tga.gov.au\/safety\/shortages\/information-about-major-medicine-shortages\/ozempic-semaglutide-shortage-2022-2025#why-doctors-cant-prescribe-semaglutide-on-the-pbs-for-weight-loss."},{"issue":"9","key":"10.1016\/j.diabres.2025.112333_b0140","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7326\/M14-1551","article-title":"The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study","volume":"162","author":"Costanzo","year":"2015","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112333_b0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4093\/dmj.2018.0055","article-title":"The evidence for an obesity paradox in type 2 diabetes mellitus","volume":"42","author":"Han","year":"2018","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2025.112333_b0150","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117698669","article-title":"World kidney day steering C. Obesity and kidney disease: hidden consequences of the epidemic","volume":"4","author":"Kovesdy","year":"2017","journal-title":"Can J Kidney Health Dis"},{"issue":"3","key":"10.1016\/j.diabres.2025.112333_b0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MNH.0000000000000212","article-title":"The dual roles of obesity in chronic kidney disease: a review of the current literature","volume":"25","author":"Rhee","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"10.1016\/j.diabres.2025.112333_b0160","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1159\/000531379","article-title":"Chronic kidney disease and obesity","volume":"147","author":"Hojs","year":"2023","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.diabres.2025.112333_b0165","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1053\/j.ajkd.2017.09.015","article-title":"Longitudinal weight change during CKD progression and its association with subsequent mortality","volume":"71","author":"Ku","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.diabres.2025.112333_b0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-011-0019-5","article-title":"Wasting in chronic kidney disease","volume":"2","author":"Mak","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"10.1016\/j.diabres.2025.112333_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/nu15071780","article-title":"The obesity paradox and mortality in older adults: a systematic review","volume":"15","author":"Drame","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.diabres.2025.112333_b0180","doi-asserted-by":"crossref","unstructured":"Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S89-S97.","DOI":"10.2337\/dc20-S008"},{"issue":"3","key":"10.1016\/j.diabres.2025.112333_b0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13340-023-00626-0","article-title":"Weight loss to disrupt type 2 diabetes","volume":"14","author":"Alsaqaaby","year":"2023","journal-title":"Diabetol Int"},{"issue":"6","key":"10.1016\/j.diabres.2025.112333_b0190","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2213-8587(20)30117-0","article-title":"Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial","volume":"8","author":"Taheri","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10120","key":"10.1016\/j.diabres.2025.112333_b0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.diabres.2025.112333_b0200","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2337\/dc23-0781","article-title":"Intensive lifestyle intervention for remission of early type 2 diabetes in primary care in Australia: DiRECT-Aus","volume":"47","author":"Hocking","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2025.112333_b0205","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2025.112333_b0210","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial","volume":"30","author":"Look","year":"2007","journal-title":"Diabetes care"},{"issue":"10278","key":"10.1016\/j.diabres.2025.112333_b0215","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10402","key":"10.1016\/j.diabres.2025.112333_b0220","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.diabres.2025.112333_b0225","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa1401329","article-title":"Bariatric surgery versus intensive medical therapy for diabetes \u2014 3-year outcomes","volume":"370","author":"Schauer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.112333_b0230","unstructured":"Empagliflozin: Australian Medicines Handbook; [updated January 2019. Available from: https:\/\/amhonline.amh.net.au.acs.hcn.com.au\/chapters\/endocrine-drugs\/drugs-diabetes\/sodium-glucose-co-transporter-2-inhibitors\/empagliflozin?menu=hints."},{"issue":"6","key":"10.1016\/j.diabres.2025.112333_b0235","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2337\/dc13-1928","article-title":"Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the look AHEAD Trial","volume":"37","author":"Rubin","year":"2014","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272500347X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272500347X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:02:20Z","timestamp":1753909340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272500347X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":47,"alternative-id":["S016882272500347X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112333","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association of weight status with glycemic control, diabetes related complications and anti-hyperglycemic medication use in patients with type 2 diabetes mellitus: The results of the Australian National Diabetes Audit (ANDA) 2015\u20132022","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112333"}}